Skip to main content
Erschienen in: Medical Oncology 1/2014

01.01.2014 | Original Paper

MACC1 overexpression predicts a poor prognosis for non-small cell lung cancer

verfasst von: Zhiqiang Wang, Zhi Li, Chen Wu, Yonggong Wang, Yang Xia, Liang Chen, Quan Zhu, Yijiang Chen

Erschienen in: Medical Oncology | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

The expression of metastasis-associated in colon cancer-1 (MACC1) in non-small cell lung cancer (NSCLC) and its association with pathological characteristics and prognosis for NSCLC patients were investigated retrospectively. The expression of MACC1 was evaluated through immunohistochemical staining of tissue microarrays from 180 samples of resected lung cancer tissues and adjacent normal lung tissues. MACC1 protein and mRNA expression were also examined from lung cancer cell lines with different metastatic potentials, 28 pairs of samples of resected fresh non-small cell lung cancer tissues, and adjacent normal lung tissues. Immunohistochemical staining of tissue microarrays showed that MACC1 was located in the cytoplasm. In addition, the expression of MACC1 protein in NSCLC was significantly higher compared to adjacent normal tissues (P < 0.001). The expression of MACC1 was positively associated with differentiation grade (P = 0.020), postoperative pathological TNM stage (P = 0.033), and lymph node metastasis (P = 0.028). Disease-free survival (DFS) and overall survival (OS) for the high MACC1 expression group were lower than the low expression group; univariate and multivariate regression analyses showed that MACC1 was an independent prognostic indicator for DFS (HR 3.124, P = 0.01) and OS (HR 2.905, P = 0.01) in NSCLC patients. The expression of MACC1 protein and mRNA was also upregulated in highly metastatic human lung cancer. In conclusion, the overexpression of MACC1 protein and mRNA may represent a potentially useful biomarker for the prognosis of NSCLC patients and might be involved in progression of NSCLC.
Literatur
2.
3.
Zurück zum Zitat Stein U, Walther W, Arlt F, Schwabe H, Smith J, Fichtner I, et al. MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med. 2009;15(1):59–67. doi:10.1038/nm.1889.PubMedCrossRef Stein U, Walther W, Arlt F, Schwabe H, Smith J, Fichtner I, et al. MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med. 2009;15(1):59–67. doi:10.​1038/​nm.​1889.PubMedCrossRef
4.
Zurück zum Zitat Kokoszynska K, Krynski J, Rychlewski L, Wyrwicz LS. Unexpected domain composition of MACC1 links MET signaling and apoptosis. Acta Biochim Pol. 2009;56(2):317–23.PubMed Kokoszynska K, Krynski J, Rychlewski L, Wyrwicz LS. Unexpected domain composition of MACC1 links MET signaling and apoptosis. Acta Biochim Pol. 2009;56(2):317–23.PubMed
6.
Zurück zum Zitat Zhang RT, Shi HR, Huang HL, Chen ZM, Liu HN, Yuan ZF. Expressions of MACC1, HGF, and C-met protein in epithelial ovarian cancer and their significance. J South Med Univ. 2011;31(9):1551–5. Zhang RT, Shi HR, Huang HL, Chen ZM, Liu HN, Yuan ZF. Expressions of MACC1, HGF, and C-met protein in epithelial ovarian cancer and their significance. J South Med Univ. 2011;31(9):1551–5.
11.
Zurück zum Zitat Kawamura M, Saigusa S, Toiyama Y, Tanaka K, Okugawa Y, Hiro J, et al. Correlation of MACC1 and MET expression in rectal cancer after neoadjuvant chemoradiotherapy. Anticancer Res. 2012;32(4):1527–31.PubMed Kawamura M, Saigusa S, Toiyama Y, Tanaka K, Okugawa Y, Hiro J, et al. Correlation of MACC1 and MET expression in rectal cancer after neoadjuvant chemoradiotherapy. Anticancer Res. 2012;32(4):1527–31.PubMed
13.
Zurück zum Zitat Chundong G, Uramoto H, Onitsuka T, Shimokawa H, Iwanami T, Nakagawa M, et al. Molecular diagnosis of MACC1 status in lung adenocarcinoma by immunohistochemical analysis. Anticancer Res. 2011;31(4):1141–5.PubMed Chundong G, Uramoto H, Onitsuka T, Shimokawa H, Iwanami T, Nakagawa M, et al. Molecular diagnosis of MACC1 status in lung adenocarcinoma by immunohistochemical analysis. Anticancer Res. 2011;31(4):1141–5.PubMed
14.
15.
Zurück zum Zitat Howington JA, Blum MG, Chang AC, Balekian AA, Murthy SC. Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer, 3rd edition: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e278S–313S. doi:10.1378/chest.12-2359.PubMedCrossRef Howington JA, Blum MG, Chang AC, Balekian AA, Murthy SC. Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer, 3rd edition: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e278S–313S. doi:10.​1378/​chest.​12-2359.PubMedCrossRef
16.
Zurück zum Zitat Ge SH, Wu XJ, Wang XH, Xing XF, Zhang LH, Zhu YB, et al. Over-expression of metastasis-associated in colon cancer-1 (MACC1) associates with better prognosis of gastric cancer patients. Chin J Cancer. 2011;23(2):153–9. doi:10.1007/s11670-011-0153-9. Ge SH, Wu XJ, Wang XH, Xing XF, Zhang LH, Zhu YB, et al. Over-expression of metastasis-associated in colon cancer-1 (MACC1) associates with better prognosis of gastric cancer patients. Chin J Cancer. 2011;23(2):153–9. doi:10.​1007/​s11670-011-0153-9.
Metadaten
Titel
MACC1 overexpression predicts a poor prognosis for non-small cell lung cancer
verfasst von
Zhiqiang Wang
Zhi Li
Chen Wu
Yonggong Wang
Yang Xia
Liang Chen
Quan Zhu
Yijiang Chen
Publikationsdatum
01.01.2014
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 1/2014
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-013-0790-6

Weitere Artikel der Ausgabe 1/2014

Medical Oncology 1/2014 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.